Trial Profile
Telaprevir in Combination With Standard of Care in Hepatitis C Genotype 1 Infection in Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- 20 Feb 2014 Status changed from recruiting to discontinued as reported by M.D. Anderson Cancer Center record.
- 20 Apr 2013 Status changed from not yet recruiting to recruiting as reported by M.D. Anderson Cancer Center record.
- 20 Apr 2013 New source identified and integrated (M.D. Anderson Cancer Center; 2012-0977).